DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

Information source: Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Type-2 Diabetes Mellitus; Coronary Artery Disease

Intervention: Ticagrelor + Aspirin (Drug); Clopidogrel + Aspirin (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Juan J Badimon

Official(s) and/or principal investigator(s):
Juan J Badimon, PhD, Principal Investigator, Affiliation: Icahn School of Medicine at Mount Sinai

Overall contact:
Juan J Badimon, PhD, Phone: (212) 241-8484, Email: Juan.Badimon@mssm.edu

Summary

The purpose of this study is to determine whether treatment with ticagrelor + aspirin is more effective than treatment with clopidogrel + aspirin in patients with type-2 diabetes. Both treatments will be given (separately) to all subjects as a one-time loading dose (i. e. higher than a normal daily dose), followed by daily dose for the next 5 to 7 days. Effectiveness of treatment will be measured with specialized blood tests before the loading dose, at two time-points after the loading dose, and once after the last daily dose.

Clinical Details

Official title: Comparative Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type 2 Diabetic Patients

Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Thrombus formation

Thrombus formation

Thrombus formation

Thrombus formation

Secondary outcome:

Platelet reactivity

Platelet reactivity

Platelet reactivity

Platelet reactivity

Vasodilator-Stimulated Phosphoprotein phosphorylation assay

Vasodilator-Stimulated Phosphoprotein phosphorylation assay

Vasodilator-Stimulated Phosphoprotein phosphorylation assay

Vasodilator-Stimulated Phosphoprotein phosphorylation assay

Detailed description: The rising prevalence of diabetes mellitus and its associated cardiovascular complications present a major burden to healthcare providers worldwide. Cardiovascular mortality is much higher among subjects with Type 2 Diabetes Mellitus (T2DM). Increased platelet reactivity is considered a potential link between the two diseases. Thus, given the higher blood thrombogenicity of T2DM with CAD, the availability of more potent antiplatelet drugs should be associated with improvements in the prevention of cardiovascular events in the diabetic populations. Ticagrelor has been shown to possess a faster onset of action and more potency than clopidogrel. Furthermore, the PLATO has shown that these characteristics results in a significant reduction in Cardiovascular events and even death as compared with Clopidogrel. We plan to compare the antithrombotic activity of ticagrelor versus clopidogrel in T2DM patients using a cross-over study design. Each participant will be randomly assigned to receive ticagrelor/clopidogrel + aspirin as a loading dose followed by 5-7 days of daily maintenance dosing. After a washout period of 1-2 weeks, each participant will receive the second treatment (clopidogrel/ticagrelor + aspirin) again as a loading dose followed by 5-7 days of daily dosing. Platelet function will be tested at pre-treatment baseline, two post-dose time-points on the day of loading dose, and one time-point after the last maintenance dose on day 5-7. Platelet testing will be carried out using the following methodologies: 1. Badimon Perfusion Chamber: an ex-vivo model of thrombosis that has been extensively utilized for evaluation of antithrombotic or prothrombotic effects under various pathological states. The model involves native blood perfusing over a thrombogenic substrate, triggering thrombus formation that can be measured by planimetry.

2. Platelet Aggregation - Multiplate Analyzer.

3. Platelet Aggregation - VerifyNow P2Y12 assay.

4. Vasodilator-Stimulated Phosphoprotein (VASP).

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosed with type-2 diabetes being treated with oral or parenteral hypoglycemic

therapy or both.

- Have not had thienopyridine therapy for at least 30 days before the study.

- Are of legal age (at least 18 years of age but less than 75 years of age) and

competent mental condition to provide written informed consent.

- For women of child-bearing potential only test negative for pregnancy at the time of

enrollment. Exclusion Criteria:

- Have a defined need for thienopyridine therapy.

- Subjects within ≤30 days of coronary artery bypass graft (CABG) surgery or

percutaneous coronary intervention (PCI).

- Known glycosylated hemoglobin (HbA1c) ≥10 mg/dL within last 3 months prior to study

entry.

- Have received fibrinolytic therapy <48 hours prior to randomization.

- Have active internal bleeding or history of bleeding diathesis.

- Have clinical findings that are, in the judgment of the investigator, associated with

an increased risk of bleeding.

- Have history of ischemic or hemorrhagic stroke, transient ischemic attack (TIA) or

intracranial neoplasm, arteriovenous malformation, or aneurysm.

- Have an International Normalized Ratio (INR) known to be >1. 5 within 1 week of study

entry.

- Have a known platelet count of <100,000/mm3 within 1 week of study entry.

- Have known anemia (hemoglobin [Hgb] <10 gm/dL) within 1 week of study entry.

- Are receiving or will receive oral anticoagulation or other antiplatelet therapy

(other than ASA) that cannot be safely discontinued for the duration of the trial.

- Are receiving daily treatment with non-steroidal anti-inflammatory drugs (NSAIDS)

that cannot be discontinued.

- Have a concomitant medical illness that in the opinion of the investigator may

interfere with or prevent completion in this study.

- Have known severe hepatic dysfunction (e. g., cirrhosis or portal hypertension).

- Have a history of intolerance or allergy to ASA or approved thienopyridines

(ticlopidine or clopidogrel).

Locations and Contacts

Juan J Badimon, PhD, Phone: (212) 241-8484, Email: Juan.Badimon@mssm.edu

Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States; Recruiting
Juan J Badimon, PhD, Principal Investigator
Additional Information

Starting date: July 2013
Last updated: May 5, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017